Evidence map›Paper›PMID 35482080›Full record

Observational studyJournal of neurology2022

Objectively assessed physiological, physical, and cognitive function along with patient-reported outcomes during the first 2 years of Alemtuzumab treatment in multiple sclerosis: a prospective observational study.

Lars G Hvid, Egon Stenager, Ulrik Dalgas

Registry-linked trialAbstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03806387 (Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03806387 completednot on this map

Physical and Cognitive Performance During the Two First Years of Lemtrada Treatment - a Prospective Observational Study

TypeobservationalSponsorUniversity of AarhusRan2017 to 2021Enrolled17ConditionsMultiple SclerosisArmsAlemtuzumab
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. MS Fatigue Post High-Efficacy Treatment.European journal of neurology · 2025
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lars G HvidExercise Biology, Department of Public Health, Aarhus University, Dalgas Avenue 4, Aarhus, Denmark. lhvid@ph.au.dk.ORCID http://orcid.org/0000-0003-3233-0429
Egon StenagerDepartment of Regional Health Research, University of Southern Denmark, Odense, Denmark.ORCID http://orcid.org/0000-0002-4877-5193
Ulrik DalgasExercise Biology, Department of Public Health, Aarhus University, Dalgas Avenue 4, Aarhus, Denmark.ORCID http://orcid.org/0000-0003-4132-2789

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn persons with multiple sclerosis (pwMS), little evidence exist on the effects of Alemtuzumab on physiological, physical, and cognitive function along with patient-reported outcomes, despite these domains are being rated as highly important. Therefore, our purpose was to perform a prospective observational study to examine these outlined outcomes during the first two years of Alemtuzumab treatment in pwMS.

methodsIn n = 17 relapsing-remitting pwMS, physiological function [body composition; bone mineral content; muscle strength; aerobic capacity], physical function [6-min walk test (6MWT, primary outcome); timed 25 ft walk test (T25FWT); six spot step test (SSST); 9-step stair ascend (9SSA); timed up and go test (TUG); 5 × sit to stand test (5STS)], cognitive function [selective reminding test (SRT); symbol digit modalities test (SDMT)], and patient-reported outcomes [multiple sclerosis impact scale-29 (MSIS29); 12-item multiple sclerosis walking scale (MSWS12); modified fatigue impact scale (MFIS); hospital anxiety and depression scale (HADS)] were assessed prior to Alemtuzumab treatment initiation as well as 3, 6, 12, and 24 months into the treatment.

resultsImprovements were observed at 24-month follow-up in T25FWT (+ 8%), SSST (+ 10%), SDMT (+ 5.2 points, 53% improved more than the clinical cut-off score) and SRT, whereas the primary outcome 6MWT, and all other remaining outcomes, remained stable throughout the Alemtuzumab treatment period.

conclusionThe present findings suggest that Alemtuzumab treatment in relapsing-remitting pwMS can improve certain domains of physical function (short distance walking) and cognitive function (processing speed, memory), and furthermore stabilize physiological and physical function along with patient-reported outcomes.

trial registrationRegistered at clinicaltrials.gov: NCT03806387.

Indexed as

Multiple SclerosisPostural BalanceAlemtuzumabCognitionHumansPatient Reported Outcome MeasuresTime and Motion StudiesWalkingAlemtuzumabCognitive functionDisease-modifying treatmentImmunomodulationMultiple sclerosisPatient-reported outcomesPhysical function

Identifiers

PMID35482080

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.